ABBV-221

ABBV-221 is an antibody drug conjugate (ADC) targeting EGFR that is being investigated to treat cancerous tumors.

Type of Molecule

Biologic

Target

EGFR

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Solid Tumors n/a
Phase 1